PBL InterferonSource has announced the expansion of its assay services portfolio to include 30 different ultra-sensitive biomolecule assays.
Based on an innovative single-molecule counting (SMCI) technology, these services are designed to provide sub-picogram per ml sensitivity for analytes in human serum or plasma.
The background reduction methodology of this detection service extends the linear dynamic range to over 4 logs, allowing high levels of biomarker measurement with minimal dilution in many disease states.
“We are proud to add ultra-sensitive cytokine detection services into our offerings to researchers around the world,” said Dr. Thomas Lavoie, Director of Product Research & Development and Assay Services at PBL.
Dr. Lavoie continued, “The ability to measure basal levels of cytokines and other biomarkers in the femtogram per ml range will enable far deeper analysis of changes in these biomarkers. This enhanced understanding of various diseases and the effects of œtreatments will allow earlier project milestone decisions, saving our clients time, money and concern.”
The addition of ultra-sensitive cytokine detection services signifies PBL’s commitment in providing the best service solutions to meet scientists’ assay needs.
It complements the company’s single-analyte ELISA, cytokine multiplex ELISA, and cell-based activity assay services that are currently offered in their sample testing and screening catalog.
Initial ultra-sensitive assay services by PBL include detection for cytokines such as human IL-17A, IL-17F, IL-17 A/F heterodimer, IL-6, IL-1α, IL-1β, IL-10, IL-15, TNF-α, GLP-1, and biomarkers such as cardiac troponin-I.